BORIS MOSHEYEV: Open Payments
NPI 1740726181 · BRONX, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$776 in 21 payments from 9 companies in 2025. Trend: 2023 $430 · 2024 $634 · 2025 $776
Food & beverage: $776
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $272 |
| Otsuka America Pharmaceutical, Inc. | 1 | $150 |
| Astellas Pharma US Inc | 3 | $101 |
| Amgen Inc. | 3 | $56 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $53 |
| ABBVIE INC. | 3 | $47 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $42 |
| ViiV Healthcare Company | 1 | $31 |
| Novo Nordisk Inc | 1 | $23 |
Products named: REXULTI, ZEPBOUND, JARDIANCE, Veozah, RELISTOR, Kerendia, OTEZLA, DOVATO.
Industry payments across NY — which companies pay providers there.
